肺结核合并慢性乙型肝炎患者治疗经验*

doi:10.3969/j.issn.1672-5069.2015.05.022

Abstract

Wei Zhenwei，Liu Yanfen，Lin Yanrong，et al.. Antiviral therapy in patients with pulmonary tuberculosis complicated by hepatitis B[J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2015, 18(5): 536-537.

[1] 中华医学会肝病学分会和感染病学分会.慢性乙型肝炎防治指南（2010年版）. 实用肝脏病杂志,2011,14（2）:81-89.
[2] World Health Organization. WHO report 2009-Global tuberculosis control[EB/OL]. [2012-12-20]. http://www.who.intftb/ publications/ global_report/2009/key_points/en/index.html.
[3] Devarbhavi H，Dierkhising R，Kremers WK，et a1.Single-center experience with drug-induced liver injury from India：causes，outcome，prognosis，and indicators of mortality. Am J Gastroenterol，2010，105（11）:2396-2404.
[4] Femandez Villar A，Sopefia B，Femandez-Villar J，et a1. The influence of risk factors on the severity of anti-tuberculosis drug-induced hepatotoxicity. Int J Tuherc Lung Dis，2004，8:1499-1505.
[5] Lee BH，Koh WJ，Choi MS，et a1. Inactive hepatitis B surface antigen carrier state and hepatotoxicity during arttitubereulasis chemotherapy. Chest，2005，127:1304-1311.
[6] Wong WM，Wu PC，Yuen MF，et a1. Antituberculosis drug-related liver dysfunction in chronic hepatitis B infection. Hepatology，2000，3l:201-206.
[7] 华医学会结核病学分会.肺结核诊断和治疗指南. 中华结核和呼吸杂志，2001，24（2）:70-74.
[8] 安慧茹，吴雪琼. 抗结核药物性肝损害研究进展. 中国抗生素杂志，2010，35（10）:727-733.
[9] Devarbhavi H，Singh R，Patil M，et a1． Outcome and determinants of mortality in 269 patients with combination anti-tuberculosis drug-induced liver injury． J Gastroenterol Hepatol，2013，28：161-167．
[10] Agal S，Baijal R，Pramanik S，et a1． Monitoring and management of antituberculosis drug induced hepatotoxicity． J Gastroenterol Hepatol，2005，20：1745-1752．
[11] Yee D，Valiquette C，Pelletier M，et a1. Incidence of serious side effects from first-1ine antituberculosis drugs among patients treated for active tuberculosis. Am J Respir Crit Care Med，2003，167:1472-1477.
[12] Chang KC，Leung CC，Yew WW.et a1. Hepatotoxicity of pyrazinamide:cohort and case-control analyses.Am J Respir Crit Care Med，2008，177:1391-1396.
[13] Makhlouf HA，Helmy A，Fawzy E，et a1.A prospective study of antituberculous drug-induced hepatotoxicity in an area endermic for liver diseases. Hepatol Int，2008，2:353-360.
[14] 徐密琴，钮志林，吴妹英. 涂阳患者分离分枝杆菌的种类及耐药性. 中国感染控制杂志，2014，21（4）:236-238.

[1]	chronic hepatitis B Zhu Lingyun, Zhang Maohai Cui Shasha, et al.. Serum IL-12 and IL-18 levels as well as peripheral blood mononuclear cell FOXp3 in patients with [J]. Journal of Practical Hepatology, 2019, 22(6): 816-819.
[2]	patients with chronic hepatitis B Zhang Yingming, Shen Shuang, Tian Fei, et al.. Prediction of response to peginterferon alfa-2a by blood IFNL4 and IL-28B gene polymorphisms in [J]. Journal of Practical Hepatology, 2019, 22(6): 828-831.
[3]	Gao Wei, Hou Yong. Diagnostic efficacy of hepatic fibrosis by liver stiffness measurement in patients with chronic hepatitis B [J]. Journal of Practical Hepatology, 2019, 22(5): 652-655.
[4]	Bai Yichun, Deng Jihong, Mei Xiaoping. Efficacy of peginterferon alfa-2b treatment and affecting response factors in patients with chronic hepatitis B [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2019, 22(4): 490-493.
[5]	Zhang Yafei, Ye Jun, Xie Qinxiu, et al. Difference in predicting efficacy of significant liver fibrosis by noninvasive liver fibrosis index in different hospitals [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2019, 22(4): 510-513.
[6]	Wang Baodan, Li Meng, Gao Yu. Predictive factors of response to interferon-α antiviral therapy in children with chronic hepatitis B [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2019, 22(3): 345-348.
[7]	Liu Liwei, Zhao Xinyan. Clinicopathological features of drug-induced liver injury [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2019, 22(2): 160-163.
[8]	Jiang Yi, Liu Bing. Comparison of clinical features and histopathological activity index between patients with chronic hepatitis B and chronic hepatitis C [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2019, 22(2): 188-191.
[9]	Huang Chunyang, Shan Jing, Liao Huiyu, Huang Yunli, Han Ying, Zhang Xiaodan, Du Xiaofei, Ren Meixin, Bian Xinqu, Liu Yanmin. Clinical and laboratory characteristics of patients with drug-induced liver injury receiving glucocorticoid therapy [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2019, 22(2): 208-211.
[10]	Wu Xiuxin, Zhang Huiyong, Zhang Kai. Changes of plasma microRNA-4284 in patients with anti-tuberculosis drug-induced hepatotoxicity [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2019, 22(2): 212-215.
[11]	Hu Hulan, Zhu Mengfei, Shi Junping.. Non-alcoholic fatty liver disease with concurrent chronic hepatitis B: What’s the progress [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2019, 22(1): 149-152.
[12]	Wang Yaofeng.. Efficacy and safety of tenofovir in the treatment of patients with chronic hepatitis B [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2018, 21(6): 847-850.
[13]	Huang Chunming, Yang Zhan, Nie Yuqiang, et al.. Prediction of liver fibrosis by gamma-glutamyl-transpeptidase-to-platelet ratio in patients with chronic hepatitis B viral infection with normal serum transaminase levels [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2018, 21(6): 859-862.
[14]	Sun Wenjing, Chen Dongfeng.. Literature analysis about RUCAM scale and Maria scale in diagnosis of Chinese patients with drug-induced liver injury [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2018, 21(6): 881-884.
[15]	Baoyan, Wang Yun, Xiang Xiaogang, et al.. Prognosis of patients with hepatocellular carcinoma and underlying hepatitis B An [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2018, 21(6): 924-927.

Antiviral therapy in patients with pulmonary tuberculosis complicated by hepatitis B

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 15

Recommended Articles

Metrics

Comments